http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jan 2025 16:03:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Press+Releases/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731 http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html <p align="center"><strong><em>NOT FOR DISTRIBUTION TO UNITED STATES</em></strong></p> <p align="justify">TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”).</p> <p align="justify">The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd. as lead underwriter and sole bookrunner (the “Lead Underwriter”), and a syndicate of underwriters (collectively with the Lead Underwriter, http://www.streetinsider.com/Globe+Newswire/Medexus+Pharmaceuticals+Announces+Overnight+Marketed+Public+Offering+of+Common+Shares/24252641.html Mon, 27 Jan 2025 16:03:00 +0000 A.05289004 MDP O.13737005 O.19742033 P731